Astellas sees Q1 revenue fall as generics almost wipe out Lexiscan sales in US

2023-08-01

临床1期财报生物类似药

Headline results for the first quarter:

Revenue: JPY 375 billion ($2.6 billion), down 1.8%

Profit: JPY 33.1 billion ($232 million), up 33.5%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

Astellas noted that while sales of key products including Xtandi, Padcev and Xospata showed "steady growth" during the first quarter, revenue from Lexiscan in the US plunged nearly 85% to JPY 29 billion due to generic competition.

Other results:

Xtandi: JPY 174.1 billion, up 7.2%

Betanis, Myrbetriq and Betmiga: JPY 49.2 billion, up 2.7%

Prograf: JPY 49.1 billion, down 5.3%

Padcev: JPY 15.2 billion, up 44.2%

Xospata: JPY 13 billion, up 24.2%

Vesicare: JPY 3.7 billion, down 8.4%

Evrenzo: JPY 1 billion, up 31%

Looking ahead:

Astellas reaffirmed that it expects revenue for fiscal year 2023 of JPY 1.52 trillion ($10.7 billion), broadly in line with the prior 12-month period, with sales of Xtandi reaching nearly JPY 670 billion ($4.7 billion billion). Meanwhile, core profit is seen growing 1.5% to JPY 228 billion ($1.6 billion).

Pipeline updates:

The company disclosed that it discontinued Phase I development of ASP0598 for chronic tympanic membrane perforation.

($1 = JPY 142.715)

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构